

# Ayse Altintas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6474703/publications.pdf>

Version: 2024-02-01

73  
papers

3,273  
citations

186265

28  
h-index

149698

56  
g-index

75  
all docs

75  
docs citations

75  
times ranked

3973  
citing authors

#	ARTICLE	IF	CITATIONS
1	A 52-Year-Old Man With Progressive Weakness and Incontinence. <i>Neurohospitalist, The</i> , 2022, 12, 194187442110395.	0.8	0
2	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 188-195.	1.9	13
3	The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103399.	2.0	6
4	A case of radiologically isolated syndrome developing Balo's concentric sclerosis lesions on long-term follow-up. <i>Neuroimmunology Reports</i> , 2022, 2, 100093.	0.4	0
5	Longitudinal Retinal Changes in <sc>MOGAD</sc>. <i>Annals of Neurology</i> , 2022, 92, 476-485.	5.3	20
6	The use of Modified Rio score for determining treatment failure in patients with multiple sclerosis: retrospective descriptive case series study. <i>Acta Neurologica Belgica</i> , 2021, 121, 1693-1698.	1.1	5
7	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	3.0	11
8	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. <i>NeuroImage: Clinical</i> , 2021, 32, 102802.	2.7	5
9	The MSBase pregnancy, neonatal outcomes, and women's health registry. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110091.	3.5	6
10	A novel investigation method for axonal damage in neuromyelitis optica spectrum disorder: In vivo corneal confocal microscopy. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732199806.	1.0	1
11	The Complex Genetic Landscape of Hereditary Ataxias in Turkey and Implications in Clinical Practice. <i>Movement Disorders</i> , 2021, 36, 1676-1688.	3.9	9
12	Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018. <i>CNS Drugs</i> , 2021, 35, 1097-1106.	5.9	7
13	Retinal Optical Coherence Tomography in Neuromyelitis Optica. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	47
14	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 912-923.	3.0	52
15	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	3.0	52
16	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1765-1774.	3.0	10
17	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.	2.0	29
18	Treatment response score to glatiramer acetate or interferon beta-1a. <i>Neurology</i> , 2020, 96, 10.1212/WNL.000000000010991.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Sex effects across the lifespan in women with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093616.	3.5	58
20	State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis. <i>Neurology and Therapy</i> , 2020, 9, 281-300.	3.2	3
21	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	7.6	24
22	Gender issues of antibody-mediated diseases in neurology: (NMOSD/autoimmune encephalitis/MG). <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642094980.	3.5	23
23	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020, 10, e035397.	1.9	10
24	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	7.6	32
25	Treatment of MOG antibody associated disorders: results of an international survey. <i>Journal of Neurology</i> , 2020, 267, 3565-3577.	3.6	64
26	A Multicenter International Study to Evaluate Different Aspects of Relationship Between MS and Pregnancy. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101537.	2.0	0
27	CD3-CD56+ NK cells display an inflammatory profile in RR-MS patients. <i>Immunology Letters</i> , 2019, 216, 63-69.	2.5	10
28	Comparative analysis of fingolimod versus teriflunomide in relapsing/remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101376.	2.0	4
29	Dysfunction of CD3 <sup>+</sup> CD16 <sup>+</sup> CD56 <sup>dim</sup> and CD3 <sup>+</sup> CD16 <sup>+</sup> CD56 <sup>bright</sup> NK cell subsets in RR-MS patients. <i>Clinical Immunology</i> , 2018, 193, 88-97.	3.2	16
30	Factors Predictive of Severe Multiple Sclerosis Disease Reactivation After Fingolimod Cessation. <i>Neurologist</i> , 2018, 23, 12-16.	0.7	23
31	Catastrophic presentation of a patient with combined NMOSD and thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a case report. <i>Acta Neurologica Belgica</i> , 2017, 117, 757-759.	1.1	2
32	Cytokine Polymorphism and HLA Genotyping in Patients with Temporal Lobe Epilepsy Related to Hippocampal Sclerosis. <i>Noropsikiyatri Arsivi</i> , 2017, 54, 350-353.	0.3	2
33	Identification of 3 Novel Patients with CLCN2-Related Leukoencephalopathy due to CLCN2 Mutations. <i>European Neurology</i> , 2017, 78, 125-127.	1.4	16
34	Next generation sequencing analysis of patients with familial cervical artery dissection. <i>European Stroke Journal</i> , 2017, 2, 137-143.	5.5	23
35	Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. <i>Multiple Sclerosis International</i> , 2016, 2016, 1-8.	0.8	30
36	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1005-1015.	1.9	228

#	ARTICLE	IF	CITATIONS
37	NMOSD with an unusual cerebral radiologic manifestation. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 7, 74-75.	2.0	1
38	Prognostic significance of pulsatile tinnitus in cervical artery dissection. <i>European Journal of Neurology</i> , 2016, 23, 1183-1187.	3.3	17
39	Sciatic neuropathy developed after injection during curettage. <i>Agri Dergisi</i> , 2016, 28, 46-48.	0.2	4
40	Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort. <i>Neurologist</i> , 2015, 20, 61-66.	0.7	8
41	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	3.0	249
42	Pregnancy Data in a Turkish Multiple Sclerosis Population. <i>European Neurology</i> , 2015, 74, 296-302.	1.4	19
43	Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1086-1094.	3.0	87
44	Familial occurrence and heritable connective tissue disorders in cervical artery dissection. <i>Neurology</i> , 2014, 83, 2023-2031.	1.1	74
45	Assessment of aquaporin-4 (AQP4) antibody assays in European diagnostic centres. <i>Journal of Neuroimmunology</i> , 2014, 275, 15.	2.3	1
46	CLIPPERS syndrome: Case report. <i>Journal of Neuroimmunology</i> , 2014, 275, 95.	2.3	1
47	BAb and MxA as Functional Biomarkers in Routine Clinical Laboratories for the Determination of Anti-IFN-Beta Antibodies and Their Bioactivity Levels in Multiple Sclerosis Patients. <i>Journal of Immunoassay and Immunochemistry</i> , 2014, 35, 398-411.	1.1	1
48	H1N1 (Domuz Gribi) AÄ±sÄ±nÄ± Takiben Ortaya Ä±kan Narkolepsi-Katapleksi Sendromu Olguları. <i>Noropsikiyatri, Arsivi</i> , 2014, 51, 283-287.	0.7	3
49	Ä±zel Durumlarda MultiplSklerozâ€™lu Hastaya YaklaÄ±m. <i>Turk Noroloji Dergisi = Turkish Journal of Neurology</i> , 2013, 19, 77-84.	0.3	1
50	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1802-1809.	3.0	133
51	Original article Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis: effect of corticosteroid therapy. <i>Folia Neuropathologica</i> , 2013, 1, 58-64.	1.2	31
52	Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1448-1453.	3.0	116
53	Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment. <i>Journal of Spinal Cord Medicine</i> , 2012, 35, 267-269.	1.4	33
54	Magnetic resonance imaging of rheumatoid meningitis: a case report and literature review. <i>Rheumatology International</i> , 2012, 32, 3679-3681.	3.0	30

#	ARTICLE	IF	CITATIONS
55	Pathological Contrast Enhancement of the Oculomotor and Trigeminal Nerves Caused by Intracranial Hypotension Syndrome. <i>Headache</i> , 2011, 51, 804-808.	3.9	8
56	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010, 352, 23-31.	1.4	86
57	<i>CADISP-Genetics</i>: An International Project Searching for Genetic Risk Factors of Cervical Artery Dissections. <i>International Journal of Stroke</i> , 2009, 4, 224-230.	5.9	68
58	The role of osteopontin: A shared pathway in the pathogenesis of multiple sclerosis and osteoporosis?. <i>Journal of the Neurological Sciences</i> , 2009, 276, 41-44.	0.6	32
59	Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease. <i>Multiple Sclerosis Journal</i> , 2009, 15, 918-927.	3.0	80
60	A cerebellar demyelinating lesion following treatment of acne with isotretinoin. <i>Clinical and Experimental Dermatology</i> , 2008, 33, 118-121.	1.3	9
61	Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. <i>Brain</i> , 2008, 131, 1759-1775.	7.6	402
62	Breathing-enhanced upper extremity exercises for patients with multiple sclerosis. <i>Clinical Rehabilitation</i> , 2007, 21, 595-602.	2.2	29
63	Pulmonary function in multiple sclerosis without any respiratory complaints. <i>Clinical Neurology and Neurosurgery</i> , 2007, 109, 242-246.	1.4	41
64	Fatigue and sleep disturbance in multiple sclerosis. <i>European Journal of Neurology</i> , 2006, 13, 1333-1339.	3.3	143
65	Headache in Behçet's Syndrome. <i>Headache</i> , 2005, 45, 911-919.	3.9	76
66	Association of <i>APOE</i> polymorphisms with disease severity in MS is limited to women. <i>Neurology</i> , 2004, 62, 811-814.	1.1	75
67	Behçet's syndrome and the nervous system. <i>Current Opinion in Neurology</i> , 2004, 17, 347-357.	3.6	156
68	Bone status in multiple sclerosis: beyond corticosteroids. <i>Multiple Sclerosis Journal</i> , 2003, 9, 600-604.	3.0	62
69	Arthritis during interferon beta-1b treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2002, 8, 534-536.	3.0	17
70	An Association between Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis and Human Leukocyte Antigens. <i>Epilepsia</i> , 2002, 43, 236-239.	5.1	25
71	Behçet's disease: diagnostic and prognostic aspects of neurological involvement. <i>Journal of Neurology</i> , 2001, 248, 95-103.	3.6	276
72	Hepatitis B vaccine related-myelitis?*. <i>European Journal of Neurology</i> , 2001, 8, 711-715.	3.3	32

#	ARTICLE	IF	CITATIONS
73	Letter to the Editor. Multiple Sclerosis Journal, 2000, 6, 364-364.	3.0	0